LUCAR G39D
Alternative Names: CD19xCD20 CAR-γδ T cell therapy - Legend Biotech; LUCAR-G39DLatest Information Update: 11 Jun 2024
At a glance
- Originator Nanjing Legend Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 09 May 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (Parenteral)(NCT06395870)
- 02 May 2024 Nanjing Legend Biotech plans a phase I trial for Non-hodgkin lymphoma (Second line therapy) in China in May 2024 (parenteral) (NCT06395870)
- 02 May 2024 Preclinical trials in Non-Hodgkin's lymphoma in China (Parenteral) prior to May 2024